Published in Proc Natl Acad Sci U S A on June 25, 2012
Nanoparticle characterization: state of the art, challenges, and emerging technologies. Mol Pharm (2013) 1.04
Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy. J Control Release (2013) 0.97
New potential for enhancing concomitant chemoradiotherapy with FDA approved concentrations of cisplatin via the photoelectric effect. Phys Med (2014) 0.91
Targeted therapy of spontaneous murine pancreatic tumors by polymeric micelles prolongs survival and prevents peritoneal metastasis. Proc Natl Acad Sci U S A (2013) 0.87
Green synthesis of platinum nanoparticles that induce cell death and G2/M-phase cell cycle arrest in human cervical cancer cells. J Mater Sci Mater Med (2015) 0.87
Design principles for clinical efficacy of cancer nanomedicine: a look into the basics. ACS Nano (2013) 0.86
Role of CFTR in oxidative stress and suicidal death of renal cells during cisplatin-induced nephrotoxicity. Cell Death Dis (2013) 0.84
Encapsulation in nanoparticles improves anti-cancer efficacy of carboplatin. AAPS PharmSciTech (2014) 0.82
Evaluation of drug loading, pharmacokinetic behavior, and toxicity of a cisplatin-containing hydrogel nanoparticle. J Control Release (2015) 0.82
Engineering of lipid prodrug-based, hyaluronic acid-decorated nanostructured lipid carriers platform for 5-fluorouracil and cisplatin combination gastric cancer therapy. Int J Nanomedicine (2015) 0.81
Supramolecular nanoparticles that target phosphoinositide-3-kinase overcome insulin resistance and exert pronounced antitumor efficacy. Cancer Res (2013) 0.78
Reporter nanoparticle that monitors its anticancer efficacy in real time. Proc Natl Acad Sci U S A (2016) 0.78
Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy. Cancer Res (2013) 0.78
Structure-based rational design of prodrugs to enable their combination with polymeric nanoparticle delivery platforms for enhanced antitumor efficacy. Angew Chem Int Ed Engl (2014) 0.77
Green Synthesis, Characterization and Uses of Palladium/Platinum Nanoparticles. Nanoscale Res Lett (2016) 0.76
Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery. Bioconjug Chem (2015) 0.76
Development of nanoscale approaches for ovarian cancer therapeutics and diagnostics. Crit Rev Oncog (2014) 0.76
Drug delivery systems for ovarian cancer treatment: a systematic review and meta-analysis of animal studies. PeerJ (2015) 0.75
Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer (2005) 13.49
Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev (2010) 12.60
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer (2007) 12.38
Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov (2005) 10.97
Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res (2006) 4.99
Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med (2004) 4.98
Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature (2005) 4.97
Cisplatin nephrotoxicity: a review. Am J Med Sci (2007) 4.05
Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res (1994) 3.54
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol (2010) 3.07
Toward complex matter: supramolecular chemistry and self-organization. Proc Natl Acad Sci U S A (2002) 2.75
PLGA-mPEG nanoparticles of cisplatin: in vitro nanoparticle degradation, in vitro drug release and in vivo drug residence in blood properties. J Control Release (2002) 2.26
The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol Ther (2009) 1.83
Platinum nephrotoxicity. Am J Med (1978) 1.73
Coexistence of passive and carrier-mediated processes in drug transport. Nat Rev Drug Discov (2010) 1.73
Relationship between complement activation, cellular uptake and surface physicochemical aspects of novel PEG-modified nanocapsules. Biomaterials (2001) 1.46
Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol (1996) 1.43
Concept and clinical evaluation of carrier-mediated anticancer agents. Oncologist (2008) 1.27
Harnessing structure-activity relationship to engineer a cisplatin nanoparticle for enhanced antitumor efficacy. Proc Natl Acad Sci U S A (2010) 1.20
Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma. Cancer Chemother Pharmacol (2003) 1.19
Characterisation of high-level cisplatin-resistant cell lines established from a human hepatoma cell line and human KB adenocarcinoma cells: cross-resistance and protein changes. Br J Cancer (1995) 1.16
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors. Clin Cancer Res (2004) 1.14
Polymeric drug delivery of platinum-based anticancer agents. J Pharm Sci (2009) 1.13
K-ras mutations in nonmucinous ovarian epithelial tumors: a molecular analysis and clinicopathologic study of 144 patients. Cancer (1998) 1.08
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.05
A small MRI contrast agent library of gadolinium(III)-encapsulated supramolecular nanoparticles for improved relaxivity and sensitivity. Biomaterials (2010) 1.02
Improved targeting of platinum chemotherapeutics. the antitumour activity of the HPMA copolymer platinum agent AP5280 in murine tumour models. Eur J Cancer (2004) 1.00
Interaction of polyethyleneglycol-phospholipid conjugates with cholesterol-phosphatidylcholine mixtures: sterically stabilized liposome formulations. Pharm Res (1996) 0.96
The therapeutic efficacy of camptothecin-encapsulated supramolecular nanoparticles. Biomaterials (2011) 0.96
Cellular pharmacokinetics of carboplatin and cisplatin in relation to their cytotoxic action. Biochem Pharmacol (1991) 0.94
An amphotericin B-ergosterol covalent conjugate with powerful membrane permeabilizing activity. Chem Biol (2004) 0.90
Rationally engineered polymeric cisplatin nanoparticles for improved antitumor efficacy. Nanotechnology (2011) 0.88
Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol (2005) 18.76
Kidney Injury Molecule-1 (KIM-1): a novel biomarker for human renal proximal tubule injury. Kidney Int (2002) 8.03
Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am J Pathol (2009) 7.34
Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell (2008) 6.54
Epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med (2010) 4.76
Ovarian cancer side population defines cells with stem cell-like characteristics and Mullerian Inhibiting Substance responsiveness. Proc Natl Acad Sci U S A (2006) 4.66
Restoration of tubular epithelial cells during repair of the postischemic kidney occurs independently of bone marrow-derived stem cells. J Clin Invest (2005) 4.10
A spatially and temporally restricted mouse model of soft tissue sarcoma. Nat Med (2007) 3.96
Urinary kidney injury molecule-1: a sensitive quantitative biomarker for early detection of kidney tubular injury. Am J Physiol Renal Physiol (2005) 3.94
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell (2011) 3.88
Normalization of urinary biomarkers to creatinine during changes in glomerular filtration rate. Kidney Int (2010) 3.78
Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle (2007) 3.62
Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol (2003) 3.61
Kidney injury molecule-1 is a phosphatidylserine receptor that confers a phagocytic phenotype on epithelial cells. J Clin Invest (2008) 3.59
Urinary N-acetyl-beta-(D)-glucosaminidase activity and kidney injury molecule-1 level are associated with adverse outcomes in acute renal failure. J Am Soc Nephrol (2007) 3.48
Neuropsychological correlates of hair arsenic, manganese, and cadmium levels in school-age children residing near a hazardous waste site. Neurotoxicology (2005) 3.12
Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol (2008) 3.10
Kidney injury molecule-1 outperforms traditional biomarkers of kidney injury in preclinical biomarker qualification studies. Nat Biotechnol (2010) 3.07
Improved performance of urinary biomarkers of acute kidney injury in the critically ill by stratification for injury duration and baseline renal function. Kidney Int (2011) 3.05
Urinary biomarkers in the clinical prognosis and early detection of acute kidney injury. Clin J Am Soc Nephrol (2010) 3.03
Chronic epithelial kidney injury molecule-1 expression causes murine kidney fibrosis. J Clin Invest (2013) 3.03
Urinary biomarkers for sensitive and specific detection of acute kidney injury in humans. Clin Transl Sci (2008) 2.98
Creatinine kinetics and the definition of acute kidney injury. J Am Soc Nephrol (2009) 2.96
Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol (2006) 2.75
Targeted proximal tubule injury triggers interstitial fibrosis and glomerulosclerosis. Kidney Int (2012) 2.74
Acute renal failure in zebrafish: a novel system to study a complex disease. Am J Physiol Renal Physiol (2004) 2.50
A rapid urine test for early detection of kidney injury. Kidney Int (2009) 2.50
Kidney tubular epithelium is restored without replacement with bone marrow-derived cells during repair after ischemic injury. Kidney Int (2005) 2.43
Conditional ablation of macrophages halts progression of crescentic glomerulonephritis. Am J Pathol (2005) 2.38
Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. J Biol Chem (2002) 2.36
YouTube as a source of information on kidney stone disease. Urology (2010) 2.36
Mesenchymal stem cells in acute kidney injury. Annu Rev Med (2008) 2.33
Associations of early childhood manganese and lead coexposure with neurodevelopment. Environ Health Perspect (2011) 2.31
Repair of injured proximal tubule does not involve specialized progenitors. Proc Natl Acad Sci U S A (2011) 2.22
Kidney injury molecule-1 (KIM-1): a urinary biomarker and much more. Nephrol Dial Transplant (2009) 2.12
Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci (2008) 2.09
India's R&D: reaching for the top. Science (2005) 2.08
Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial. Am J Kidney Dis (2008) 2.05
High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation (2007) 2.01
Prenatal exposure to mercury and fish consumption during pregnancy and attention-deficit/hyperactivity disorder-related behavior in children. Arch Pediatr Adolesc Med (2012) 1.98
Testosterone is responsible for enhanced susceptibility of males to ischemic renal injury. J Biol Chem (2004) 1.96
Comparison of kidney injury molecule-1 and other nephrotoxicity biomarkers in urine and kidney following acute exposure to gentamicin, mercury, and chromium. Toxicol Sci (2007) 1.94
Renal injury is a third hit promoting rapid development of adult polycystic kidney disease. Hum Mol Genet (2009) 1.94
Urinary liver-type fatty acid-binding protein predicts adverse outcomes in acute kidney injury. Kidney Int (2009) 1.94
Cytosolic phospholipase A2alpha is crucial [correction of A2alpha deficiency is crucial] for 'on-time' embryo implantation that directs subsequent development. Development (2002) 1.91
Tubular kidney injury molecule-1 in protein-overload nephropathy. Am J Physiol Renal Physiol (2006) 1.85
Simvastatin reduces venous stenosis formation in a murine hemodialysis vascular access model. Kidney Int (2013) 1.83
Targeting Notch, a key pathway for ovarian cancer stem cells, sensitizes tumors to platinum therapy. Proc Natl Acad Sci U S A (2012) 1.81
KIM-1-mediated phagocytosis reduces acute injury to the kidney. J Clin Invest (2015) 1.80
Imperfect gold standards for kidney injury biomarker evaluation. J Am Soc Nephrol (2011) 1.79
Protection of renal epithelial cells against oxidative injury by endoplasmic reticulum stress preconditioning is mediated by ERK1/2 activation. J Biol Chem (2003) 1.78
Comparative analysis of urinary biomarkers for early detection of acute kidney injury following cardiopulmonary bypass. Biomarkers (2009) 1.77
Effects of oral contraceptives or a gonadotropin-releasing hormone agonist on ovarian carcinogenesis in genetically engineered mice. Cancer Prev Res (Phila) (2009) 1.75
Biologic markers for the early detection of acute kidney injury. Curr Opin Crit Care (2004) 1.75
Release of free F2-isoprostanes from esterified phospholipids is catalyzed by intracellular and plasma platelet-activating factor acetylhydrolases. J Biol Chem (2005) 1.73
Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol (2005) 1.71
Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase. Kidney Int (2010) 1.67
Kidney injury molecule-1 expression in murine polycystic kidney disease. Am J Physiol Renal Physiol (2002) 1.64
Inducible nitric-oxide synthase is an important contributor to prolonged protective effects of ischemic preconditioning in the mouse kidney. J Biol Chem (2003) 1.63
Rapid screening of glomerular slit diaphragm integrity in larval zebrafish. Am J Physiol Renal Physiol (2007) 1.63
Early postnatal blood manganese levels and children's neurodevelopment. Epidemiology (2010) 1.58
Smartphone apps as a source of cancer information: changing trends in health information-seeking behavior. J Cancer Educ (2013) 1.57
Pathophysiology of acute kidney injury to chronic kidney disease: maladaptive repair. Contrib Nephrol (2011) 1.57
Biomarkers of nephrotoxic acute kidney injury. Toxicology (2008) 1.55
Some biomarkers of acute kidney injury are increased in pre-renal acute injury. Kidney Int (2012) 1.55
Endoscopic retrograde cholangiopancreatography complications in the era of cholangioscopy: is there an increased risk? Dig Liver Dis (2012) 1.53
Immunolocalization of Kim-1, RPA-1, and RPA-2 in kidney of gentamicin-, mercury-, or chromium-treated rats: relationship to renal distributions of iNOS and nitrotyrosine. Toxicol Pathol (2008) 1.51
T cell, Ig domain, mucin domain-2 gene-deficient mice reveal a novel mechanism for the regulation of Th2 immune responses and airway inflammation. J Immunol (2006) 1.51
Tubular damage in chronic systolic heart failure is associated with reduced survival independent of glomerular filtration rate. Heart (2010) 1.50
Mineralocorticoid receptor blockade confers renoprotection in preexisting chronic cyclosporine nephrotoxicity. Am J Physiol Renal Physiol (2006) 1.47
A child with chronic manganese exposure from drinking water. Environ Health Perspect (2002) 1.47
NADPH oxidase p22phox and catalase gene variants are associated with biomarkers of oxidative stress and adverse outcomes in acute renal failure. J Am Soc Nephrol (2006) 1.46
Urinary expression of novel tissue markers of kidney injury after ureteroscopy, shockwave lithotripsy, and in normal healthy controls. J Endourol (2013) 1.46
Lead, diabetes, hypertension, and renal function: the normative aging study. Environ Health Perspect (2004) 1.45
Modulation of aquaporin-2/vasopressin2 receptor kidney expression and tubular injury after endotoxin (lipopolysaccharide) challenge. Crit Care Med (2008) 1.44
Prevention of kidney ischemia/reperfusion-induced functional injury, MAPK and MAPK kinase activation, and inflammation by remote transient ureteral obstruction. J Biol Chem (2001) 1.43
Principles of physics in surgery: the laws of mechanics and vectors physics for surgeons-part 2. Indian J Surg (2010) 1.41
Creatinine as the gold standard for kidney injury biomarker studies? Nephrol Dial Transplant (2009) 1.39
Induction of kidney injury molecule-1 in homozygous Ren2 rats is attenuated by blockade of the renin-angiotensin system or p38 MAP kinase. Am J Physiol Renal Physiol (2006) 1.36
Defect in regulatory B-cell function and development of systemic autoimmunity in T-cell Ig mucin 1 (Tim-1) mucin domain-mutant mice. Proc Natl Acad Sci U S A (2012) 1.35
Test characteristics of urinary biomarkers depend on quantitation method in acute kidney injury. J Am Soc Nephrol (2011) 1.35
Loss of leucine-rich repeat kinase 2 causes age-dependent bi-phasic alterations of the autophagy pathway. Mol Neurodegener (2012) 1.34
The Sweet Pee model for Sglt2 mutation. J Am Soc Nephrol (2011) 1.32
Systemic microvascular leak in an in vivo rat model of ventilator-induced lung injury. Am J Respir Crit Care Med (2003) 1.32
Rapid self-healing hydrogels. Proc Natl Acad Sci U S A (2012) 1.29
A highly conserved tyrosine of Tim-3 is phosphorylated upon stimulation by its ligand galectin-9. Biochem Biophys Res Commun (2006) 1.29
HIF in kidney disease and development. J Am Soc Nephrol (2008) 1.28
Regulation of HAX-1 anti-apoptotic protein by Omi/HtrA2 protease during cell death. J Biol Chem (2004) 1.28
A framework and key research questions in AKI diagnosis and staging in different environments. Clin J Am Soc Nephrol (2008) 1.27
Associations of urinary levels of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) with kidney function decline in the Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis (2012) 1.27
Orchiectomy attenuates post-ischemic oxidative stress and ischemia/reperfusion injury in mice. A role for manganese superoxide dismutase. J Biol Chem (2006) 1.25
Deletion of secretory group V phospholipase A2 attenuates cell migration and airway hyperresponsiveness in immunosensitized mice. J Immunol (2007) 1.25
Mechanistic biomarkers for cytotoxic acute kidney injury. Expert Opin Drug Metab Toxicol (2006) 1.24
Stretch-induced IL-8 depends on c-Jun NH2-terminal and nuclear factor-kappaB-inducing kinases. Am J Physiol Lung Cell Mol Physiol (2003) 1.24
Effect of breast milk lead on infant blood lead levels at 1 month of age. Environ Health Perspect (2004) 1.23